+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class, Route of Administration, and Distribution Channel

  • ID: 5359924
  • Report
  • May 2021
  • Region: North America
  • 130 pages
  • The Insight Partners
UP TO OFF
until Sep 30th 2021

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • F. HOFFMANN-LA ROCHE LTD
  • Horizon Therapeutics plc
  • Merck & Co., Inc.
  • Novartis AG
The immunosuppressants segment by drug class is estimated to lead the market growth during the forecast period.



According to this study, the North America multiple sclerosis therapeutics market is expected to reach US$ 15,269.74 million by 2027 from US$ 9,144.98 million in 2019; it is estimated to grow at a CAGR of 6.8% from 2020 to 2027. The report highlights trends prevailing in the North America multiple sclerosis therapeutics market and the factors driving market along with those that act as hindrances.

The North America multiple sclerosis therapeutics market, by drug class, is segmented into immunosuppressant and immunomodulators. The immunomodulators segment held the largest share of the market in 2019, whereas the immunosuppressants segment is anticipated to register the highest CAGR in the market during the forecast period.

As per the National Multiple Sclerosis Society’s study in 2017, about 1 million adults (up to 913,925) were suffering from MS in the US. Therefore, the growing prevalence of multiple sclerosis is driving the growth of the North America multiple sclerosis therapeutics market. Due to rise in funding, extensive research is being carried on developing novel medicines and treatments for multiple sclerosis and other ways of identifying potential causes for multiple sclerosis. Various organizations such as National Institute of Neurological Disorders and Stroke, National MS Society, and Parkinson’s Action Network are undertaking extensive efforts to create novel therapies for MS, which is driving the growth of the market.

North America is recording the growing number of COVID-19 cases. Patients suffering from chronic health conditions, such as neurological diseases, are reporting delays in treatment. Several companies are cutting their clinical trial activities and delaying product launches in response to the COVID-19 pandemic. However, amid pandemic, many companies and research institutes in the US are taking an initiative to study the neurological manifestations of COVID-19. To accelerate research into the diagnosis, prevention, and treatment of the neurological complications due to COVID-19, several initiatives have been initiated. These factors are positively influencing the North America multiple sclerosis therapeutics market to a extent.

The growth of the market is attributed to some key driving factors such as increasing prevalence of multiple sclerosis and rise in funding for multiple sclerosis research. However, the high cost of the multiple sclerosis treatment may hinder the market growth.

Merck & Co., Inc., Novartis AG, Bayer AG, Sanofi, Bristol-Myers Squibb Company, Horizon Therapeutics plc, TEVA PHARMACEUTICAL INDUSTRIES LTD, Takeda Pharmaceutical Company Limited, F. HOFFMANN-LA ROCHE LTD, and Biogen are among the leading companies operating in the North America multiple sclerosis therapeutics market.

The report segments in North America Multiple Sclerosis Therapeutics Market as follows:

By Drug Class
  • Immunosuppressant
  • Immunomodulators
By Route of Administration
  • Injectable
  • Oral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
By Country
  • US
  • Canada
  • Mexico
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • F. HOFFMANN-LA ROCHE LTD
  • Horizon Therapeutics plc
  • Merck & Co., Inc.
  • Novartis AG
1. Introduction
1.1 Scope of the Study
1.2 The Publisher's Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Multiple Sclerosis Therapeutics Market - By Drug Class
1.3.2 North America Multiple Sclerosis Therapeutics Market - By Route of Administration
1.3.3 North America Multiple Sclerosis Therapeutics Market - By Distribution Channel
1.3.4 North America Multiple Sclerosis Therapeutics Market - By Country

2. Multiple Sclerosis Therapeutics Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Multiple Sclerosis Therapeutics- Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.3 Expert Opinions

5. Multiple Sclerosis Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Multiple Sclerosis (MS)
5.1.2 Rising Funding for Multiple Sclerosis Research
5.2 Market Restraints
5.2.1 High Cost of Multiple Sclerosis Treatment
5.3 Market Opportunities
5.3.1 Increasing Awareness About Multiple Sclerosis
5.4 Future Trends
5.4.1 Development and Launch of Innovative Products
5.5 Impact analysis

6. Multiple Sclerosis Therapeutics Market - North America Analysis
6.1 North America Multiple Sclerosis Therapeutics Market Revenue Forecast and Analysis

7. Multiple Sclerosis Therapeutics Market Analysis - By Drug Class
7.1 Overview
7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Immunosuppressant
7.3.1 Overview
7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Immunomodulators
7.4.1 Overview
7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

8. Multiple Sclerosis Therapeutics Market Analysis - By Route of Administration
8.1 Overview
8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
8.3 Injectable
8.3.1 Overview
8.3.2 Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Oral
8.4.1 Overview
8.4.2 Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

9. Multiple Sclerosis Therapeutics Market Analysis - By Distribution Channel
9.1 Overview
9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.5 E-Commerce
9.5.1 Overview
9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

10. Multiple Sclerosis Therapeutics Market Analysis and Forecast To 2027 - North America Analysis
10.1 North America: Multiple Sclerosis Therapeutics Market
10.1.1 Overview
10.1.2 North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
10.1.3 US: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.3.1 US: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.3.2 US: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
10.1.3.3 US: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
10.1.3.4 US: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018-2027 (USD Million)
10.1.4 Canada: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.4.1 Canada: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.4.2 Canada: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
10.1.4.3 Canada: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
10.1.4.4 Canada: Multiple Sclerosis Therapeutics Market, by Distribution Channel 2018-2027 (USD Million)
10.1.5 Mexico: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.5.1 Mexico: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.5.2 Mexico: Multiple Sclerosis Therapeutics Market, by Drug Class, 2018-2027 (USD Million)
10.1.5.3 Mexico: Multiple Sclerosis Therapeutics Market, by Route of Administration 2018-2027 (USD Million)
10.1.5.4 Mexico: Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2018-2027 (USD Million)

11. Impact of COVID-19 Pandemic on North America Multiple Sclerosis Therapeutics Market
11.1 North America: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview

13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Novartis AG
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Horizon Therapeutics plc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Takeda Pharmaceutical Company Limited
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 F. HOFFMANN-LA ROCHE LTD.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Biogen
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms

List of Tables
Table 1. US Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 2. US Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 3. US Multiple Sclerosis Therapeutics Market, by Distribution Channel- Revenue and Forecast to 2027 (USD Million)
Table 4. Canada Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 5. Canada Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 6. Canada Multiple Sclerosis Therapeutics Market, by Distribution Channel- Revenue and Forecast to 2027 (USD Million)
Table 7. Mexico Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 8. Mexico Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 9. Mexico Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
Table 10. Organic Developments Done by Companies
Table 11. Inorganic Developments Done By Companies
Table 12. Glossary of Terms, Multiple sclerosis therapeutics Market

List of Figures
Figure 1. Multiple Sclerosis Therapeutics Market Segmentation
Figure 2. Multiple Sclerosis Therapeutics Market Segmentation, By Country
Figure 3. Multiple Sclerosis Therapeutics Market Overview
Figure 4. Immunomodulators Segment by Drug Class Held the Larger Share
Figure 5. North America Multiple Sclerosis Therapeutics Market, by Country (US$ Million)
Figure 6. North America PEST Analysis
Figure 7. Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. North America Multiple Sclerosis Therapeutics Market - Revenue Forecast and Analysis - 2019- 2027
Figure 9. Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
Figure 10. Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 11. Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 12. Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
Figure 13. Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 14. Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 15. Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
Figure 16. Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 17. Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 18. E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 19. North America: Multiple Sclerosis Therapeutics Market, by Key Country - Revenue (2019) (USD Million)
Figure 20. North America: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 21. US: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 22. Canada: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 23. Mexico: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 24. Impact of COVID-19 Pandemic in North American Country Markets
Note: Product cover images may vary from those shown
  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • Horizon Therapeutics plc
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Takeda Pharmaceutical Company Limited
  • F. HOFFMANN-LA ROCHE LTD
  • Biogen
Note: Product cover images may vary from those shown
Adroll
adroll